Physician profile
David Naai
NPI 1578568416
$4,805.15
in general payments reported to CMS, 2019-2025
22 companies · $1,768 in 2025
The $1,768 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $142 · 2021: $262 · 2022: $690 · 2023: $647 · 2024: $948 · 2025: $1,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,345 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,345.45 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,294.39 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $450.27 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $435.12 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $282.79 | 2024-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $273.71 | 2022-2025 | Lupkynis |
| Travere Therapeutics, INC. | $266.42 | 2022-2025 | Filspari |
| Nxstage Medical, INC. | $249.32 | 2022-2025 | Nxstage System One, Nxstage Pureflow Solution, Nxstage Cartridge Express |
| Kls-Martin L.P. | $214.88 | 2019 | |
| Vifor Pharma, INC. | $210.56 | 2019-2024 | |
| Glaxosmithkline, LLC. | $205.87 | 2021-2025 | Benlysta |
| Horizon Therapeutics Plc | $201.74 | 2022-2023 | Krystexxa |
| Akebia Therapeutics INC | $159.46 | 2025 | Vafseo |
| Novartis Pharmaceuticals Corporation | $146.42 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $121.84 | 2024 | Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.35 | 2024-2025 | Jardiance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $44.99 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $43.03 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $36.40 | 2021 | |
| Mallinckrodt Enterprises LLC | $24.99 | 2019 | |
| Pfizer INC. | $23.65 | 2023 | |
| Abbvie INC. | $22.44 | 2025 | |
| Scpharmaceuticals INC. | $17.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Naai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.